AbolerIS Pharma

AbolerIS Pharma is a biopharmaceutical company dedicated to developing innovative therapeutics that regulate the immune system, targeting unmet needs in autoimmune disorders. Founded in 2019 in Nantes, France, AbolerIS Pharma focuses on advanced biopharmaceuticals for autoimmune conditions. The company has completed a total of 3 deals, with the most recent funding round occurring on May 27, 2021, securing EUR 1. 25 million.

The company is led by CEO Ann Meulemans and was founded by Carole Guillonneau. Aboleris Pharma specializes in novel therapeutics aimed at regulating the immune system. Their core product offerings focus on advanced biopharmaceuticals that target autoimmune disorders and enhance immune response. These therapeutics address significant unmet medical needs in conditions like rheumatoid arthritis, lupus, and multiple sclerosis, among others.

Aboleris Pharma's products are engineered using proprietary technology that modulates immune pathways to achieve targeted therapeutic effects. The company serves a diverse client base, including healthcare providers, research institutions, and pharmaceutical distributors, primarily in North America and Europe. Aboleris Pharma generates revenue through a combination of direct sales and strategic partnerships with healthcare providers and research institutions. Transactions typically occur through a business-to-business model, where products are sold to hospitals, clinics, and specialty pharmacies.

The company's flagship products are integrated into treatment protocols for various autoimmune conditions, and pricing is structured to reflect the value provided to healthcare providers and patients alike. Revenue is driven by both the volume of products sold and agreements established with partner organizations for clinical trials and post-market studies. In May 2021, AbolerIS Pharma raised EUR 1. 25 million in funding to support its future growth initiatives.

The company is focused on launching new products designed to enhance immune regulation, although specific release dates have not been disclosed. Additionally, AbolerIS Pharma plans to expand into new markets in Europe and North America by 2023, aiming to increase its footprint in these regions. The recent funding will be utilized to accelerate product development and strengthen partnerships with healthcare institutions.